Hovione

Belkins
Hovione has over 57 years of experience as a CDMO and is currently a fully integrated supplier offering from drug substance to drug product intermediate to drug product. With four FDA inspected sites, USA, China, Ireland and Portugal and development laboratories in Lisbon, Portugal and New Jersey, USA, Hovione provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs including highly potent compounds. For generic pharmaceutical customers, the company offers niche off-patent API products. Hovione also provides proprietary product development and licensing opportunities for drug products.

Related News

KIMERA® LABS FILES FIRST FDA INVESTIGATIONAL NEW DRUG (IND) APPLICATION USING XOGLO® FOR TREATMENT OF ARDS SECONDARY TO COVID-19

Prnewswire | August 18, 2020

news image

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...

Read More

PHARMACY MARKET

REGIS EXPANDS FACILITIES TO SUPPORT RISING DEMAND FOR U.S.-BASED CUSTOM API PHARMACEUTICAL DEVELOPMENT AND MANUFACTURING

Regis | February 18, 2021

news image

Regis Technologies, Inc. today reported the culmination of a significant extension of their laboratory facilities for the development of dynamic pharmaceutical ingredients (APIs) situated in Morton Grove, Illinois. The extension, which pairs the organization's ability to take on new development projects, is currently completely operational. It expands capacities across Regis' custom pharmaceutical service contributions, including analytical development, process chemistry, solid state che...

Read More

ANTI-PARASITIC DRUG HALTS CORONAVIRUS REPLICATION IN LAB-GROWN CELLS WITHIN 48 HOURS

GEN | April 06, 2020

news image

An anti-parasitic drug that is available around the world stops SARS-CoV-2 coronavirus from replicating in cells within a couple of days, according to findings from in vitro studies by Monash University’s Biomedicine Discovery Institute (BDI), working with the Peter Doherty Institute of Infection and Immunity. BDI research lead Kylie Wagstaff, PhD, said the studies showed that the drug, ivermectin, started to become effective against SARS-CoV-2 in lab-grown cells within just a day. “...

Read More

BUSINESS INSIGHTS

QUOTIENT SCIENCES ACQUIRES ARCINOVA

Quotient Sciences, Arcinova | February 09, 2021

news image

Quotient Sciences, the drug development and manufacturing accelerator, reported that it has procured Arcinova, the U.K.- based multiservice contract development and manufacturing organization (CDMO). With more than 40 years of involvement and 160 representatives, Arcinova gives drug substance, drug item and bioanalysis administrations to more than 200 pharma and biotech clients around the world. The obtaining expands Quotient's administration portfolio and will empower the inc...

Read More

Prnewswire | August 18, 2020

news image

KIMERA® LABS FILES FIRST FDA INVESTIGATIONAL NEW DRUG (IND) APPLICATION USING XOGLO® FOR TREATMENT OF ARDS SECONDARY TO COVID-19

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...

Read More

PHARMACY MARKET

Regis | February 18, 2021

news image

REGIS EXPANDS FACILITIES TO SUPPORT RISING DEMAND FOR U.S.-BASED CUSTOM API PHARMACEUTICAL DEVELOPMENT AND MANUFACTURING

Regis Technologies, Inc. today reported the culmination of a significant extension of their laboratory facilities for the development of dynamic pharmaceutical ingredients (APIs) situated in Morton Grove, Illinois. The extension, which pairs the organization's ability to take on new development projects, is currently completely operational. It expands capacities across Regis' custom pharmaceutical service contributions, including analytical development, process chemistry, solid state che...

Read More

GEN | April 06, 2020

news image

ANTI-PARASITIC DRUG HALTS CORONAVIRUS REPLICATION IN LAB-GROWN CELLS WITHIN 48 HOURS

An anti-parasitic drug that is available around the world stops SARS-CoV-2 coronavirus from replicating in cells within a couple of days, according to findings from in vitro studies by Monash University’s Biomedicine Discovery Institute (BDI), working with the Peter Doherty Institute of Infection and Immunity. BDI research lead Kylie Wagstaff, PhD, said the studies showed that the drug, ivermectin, started to become effective against SARS-CoV-2 in lab-grown cells within just a day. “...

Read More

BUSINESS INSIGHTS

Quotient Sciences, Arcinova | February 09, 2021

news image

QUOTIENT SCIENCES ACQUIRES ARCINOVA

Quotient Sciences, the drug development and manufacturing accelerator, reported that it has procured Arcinova, the U.K.- based multiservice contract development and manufacturing organization (CDMO). With more than 40 years of involvement and 160 representatives, Arcinova gives drug substance, drug item and bioanalysis administrations to more than 200 pharma and biotech clients around the world. The obtaining expands Quotient's administration portfolio and will empower the inc...

Read More